<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817111</url>
  </required_header>
  <id_info>
    <org_study_id>19-016525</org_study_id>
    <secondary_id>MIB-626-201</secondary_id>
    <nct_id>NCT04817111</nct_id>
  </id_info>
  <brief_title>NAD+ Precursor Supplementation in Friedreich's Ataxia</brief_title>
  <official_title>A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metro International Biotech, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Metro International Biotech, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to test the safety and tolerability of short-term therapy with a&#xD;
      nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's&#xD;
      Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%.&#xD;
      A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle&#xD;
      bioenergetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary focus for this protocol is safety and tolerability. We will systematically assess&#xD;
      for adverse events using a safety monitoring uniform report form. We will also use cardiac&#xD;
      31-Phosphorus-Magnetic Resonance Spectroscopy (MRS) to measure the&#xD;
      Phosphocreatine(PCr)/Adenosine triphosphate (ATP)- γ ratio before and after treatment with&#xD;
      MIB-626. In addition, if time permits we will use proton (1H)-MRS to measure skeletal muscle&#xD;
      nicotinamide adenine dinucleotide (NAD+) before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2021</start_date>
  <completion_date type="Anticipated">April 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label, 14 Days (+/- 2 Days)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by Common Terminology Criteria for Adverse Events version 5.0.</measure>
    <time_frame>14 Days</time_frame>
    <description>Safety will be monitored through collection of laboratory assessments (CBC, CMP, lipid profile, HbA1c), vital signs (heart rate, blood pressure), and ECG, all of which will be reviewed for clinically relevant abnormalities, and standardized assessment of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac 31-Phosphorus-MRS: PCr/ATP Ratio</measure>
    <time_frame>Change from baseline to 14 days.</time_frame>
    <description>Measure the within-participant change in PCr/ATP-γ ratio before and after treatment with MIB-626.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Exercise CrCEST</measure>
    <time_frame>Change from baseline to 14 days.</time_frame>
    <description>Assess the within-participant change in skeletal muscle post-exercise CrCEST recovery (an index of skeletal muscle mitochondrial oxidative phosphorylation capacity) and the within-participant change skeletal muscle NAD+ via 1H-MRS before and after treatment with MIB-626.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>Change from baseline to 14 days.</time_frame>
    <description>Assess within-participant changes in grip strength (via hand grip dynamometry) before and after treatment with MIB-626.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of NAD+ in Whole Blood</measure>
    <time_frame>Change from baseline to 14 days.</time_frame>
    <description>Measure the concentration of NAD+ (and associated metabolites) in whole blood before and after treatment with MIB-626.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Open Label - MIB-626</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MIB-626</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIB-626</intervention_name>
    <description>Two (2) 500 mg Tablets, By Mouth, Daily</description>
    <arm_group_label>Open Label - MIB-626</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Molecular diagnosis of Friedreich's Ataxia (FA).&#xD;
&#xD;
          -  Males and females, ages 18 years to &lt; 65 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to nicotinamide-containing compounds.&#xD;
&#xD;
          -  Concurrent use of Vitamin B3 supplements and/or any medications likely to increase&#xD;
             risk of MIB-626 toxicity.&#xD;
&#xD;
          -  HgbA1c &gt; (great than or equal to) 8.5% and or Diabetes Mellitus (DM) requiring insulin&#xD;
             or insulin secretagogue.&#xD;
&#xD;
          -  Kidney disease (Estimated Glomerular Filtration Rate (eGFR) &lt; 60 ml/min/1.73 m2) using&#xD;
             serum creatinine and MDRD equation. The eGFR levels will be calculated using the&#xD;
             Modified Diet in Renal Disease Study (MDRD) equation, which is the equation used by&#xD;
             the Children's Hospital Of Philadelphia laboratory.&#xD;
&#xD;
          -  Liver disease (Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) &gt; 3 x&#xD;
             Upper Limit of Normal)&#xD;
&#xD;
          -  Severe co-existing cardiac disease (Ejection Fraction (EF) &lt; 40%, known arrhythmia) as&#xD;
             demonstrated by an echocardiogram within 12 months of screening.&#xD;
&#xD;
          -  Any contraindication to MRI, including spinal rods (related to unknown safety&#xD;
             considerations for cardiac 31-Phosphorus -MRS).&#xD;
&#xD;
          -  Use of any investigational agent within 4 weeks of enrollment.&#xD;
&#xD;
          -  Females: Pregnant/lactating or planning to become pregnant during their participation.&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shana E McCormack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin L Wade, MLitt</last_name>
    <phone>(267) 426-8724</phone>
    <email>wadekl@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna DeDio, MPH</last_name>
    <phone>(267) 425-1998</phone>
    <email>dedioa@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin L. Wade, MLitt</last_name>
      <phone>267-398-5761</phone>
      <email>wadekl@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna DeDio, MPH</last_name>
      <phone>(267) 425-1998</phone>
      <email>dedioa@chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shana E McCormack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DeBrosse C, Nanga RPR, Wilson N, D'Aquilla K, Elliott M, Hariharan H, Yan F, Wade K, Nguyen S, Worsley D, Parris-Skeete C, McCormick E, Xiao R, Cunningham ZZ, Fishbein L, Nathanson KL, Lynch DR, Stallings VA, Yudkoff M, Falk MJ, Reddy R, McCormack SE. Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. JCI Insight. 2016 Nov 3;1(18):e88207. doi: 10.1172/jci.insight.88207.</citation>
    <PMID>27812541</PMID>
  </reference>
  <reference>
    <citation>Bagga P, Wilson N., DeBrosse D., Hariharan H., Reddy R., editor. In vivo detection of NAD+ in human calf muscle at 7T using 28-channel knee volume coil. International Society for Magnetic Resonance in Medicine; 2019; Montreal, Canada.</citation>
  </reference>
  <reference>
    <citation>Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C, Foerster D, Shinnick J, Schadt K, Yiu EM, Delatycki MB, Perlman S, Wilmot GR, Zesiewicz T, Mathews K, Gomez CM, Yoon G, Subramony SH, Brocht A, Farmer J, Lynch DR. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016 Jul 25;3(9):684-94. doi: 10.1002/acn3.332. eCollection 2016 Sep.</citation>
    <PMID>27648458</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Shana McCormack</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD may be available with appropriate regulatory approvals.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

